Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAglio: Bevacizumab in Newly Diagnosed Glioblastoma
NCT00943826Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2009
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Bevacizumab + RT + Temozolomide with Placebo + RT + Temozolomide (2 arms). Primary endpoints: Progression-free Survival as Assessed by Investigator up to 31.4 months and Overall Survival up to 42.2 months. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00943826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943826.